Abstract
Peptide receptor radionuclide therapy is an effective treatment option for patients with well-differentiated somatostatin receptor-expressing neuroendocrine tumors. However, published data result mainly from retrospective monocentric studies. We initiated a multi-institutional, prospective, board-reviewed registry for patients treated with peptide receptor radionuclide therapy in Germany in 2009. In five centers, 297 patients were registered. Primary tumors were mainly derived from pancreas (117/297) and small intestine (80/297), whereas 56 were of unknown primary. Most tumors were well differentiated with median Ki67 proliferation rate of 5% (range 0.9–70%). Peptide receptor radionuclide therapy was performed using mainly yttrium-90 and/or lutetium-177 as radionuclides in 1–8 cycles. Mean overall survival was estimated at 213 months with follow-up between 1 and 230 months after initial diagnosis, and 87 months with follow-up between 1 and 92 months after start of peptide receptor radionuclide therapy. Median overall survival was not yet reached. Subgroup analysis demonstrated that best results were obtained in neuroendocrine tumors with proliferation rate below 20%. Our results indicate that peptide receptor radionuclide therapy is an effective treatment for well- and moderately differentiated neuroendocrine tumors irrespective of previous therapies and should be regarded as one of the primary treatment options for patients with somatostatin receptor-expressing neuroendocrine tumors.
Keywords
- Proliferation Rate
- Neuroendocrine Tumor
- Proliferation Index
- Peptide Receptor Radionuclide Therapy
- Previous Therapy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bushnell DL Jr, O’Dorisio TM, O’Dorisio MS et al (2010) 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28:1652–1659
de Jong M, Breeman WA, Bernard HF et al (1999) Therapy of neuroendocrine tumours with radiolabeled somatostatin-analogues. Q J Nucl Med 43:356–366
Hörsch D, Prasad V, Petrovitch A, Baum RB (2010) Combined treatment of rapidly progressing neuroendocrine tumors by transcatheter arterial chemoembolisation of the liver and peptide-receptor radiotherapy is safe and effective: Report of 30 consecutive patients. J Clin Oncol 28(suppl):e14634 (abstr)
Imhof A, Brunner P, Marincek N et al (2011) Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 22:2416–2423
Kwekkeboom D, de Herder W, Kam B et al (2008) Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130
Kwekkeboom DJ, Kam Bl, van Essen M et al (2010) Somatostatin receptor based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 17:R53–R73
Merola E, Capurso G, Campana D (2010) Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid. Dig Liver Dis 42:457–458
Pape UF, Jann H, Müller-Nordhorn J et al (2008) Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 113:256–265
Raymond E, Niccoli P, Raoul J et al (2011) Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). J Clin Oncol 29(suppl):4008 (abstr)
Rollman EJ, Melis M, Valkema R (2010) Kidney protection during peptide receptor radionuclide therapy with somatostatin analoques. Eur J Nucl Mol Imaging 37:1018–1031
Rufini V, Calcagni ML, Baum RP (2006) Imaging of neuroendocrine tumors. Semin Nucl Med 36:228–247
Seregni E, Maccauro M, Coliva A et al (2010) Treatment with tandem [(90)Y] DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results. Q J Nucl Med Mol Imaging 54(1):84–91
Strosberg J, Cheema A, Weber J et al (2011) Prognostic validity of a novel American joint committee on cancer staging classification for pancreatic neuroendocrine tumors. J Clin Oncol 29:3044–3049
Valkema R, Pauwels S, Kvols LK et al (2006) Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 36:147–156
Wehrmann C, Senftleben S, Zachert C (2007) Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 22:406–416
Yao JC, Hassan M, Phan A et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072
Zaknun JJ et al. (eds) Practical guidance on peptide receptor radionuclide therapy (PRRNT) for neuroendocrine tumors. (in press IAEA)
Acknowledgments
We are indebted to all patients who agreed to be registered. The registry of peptide receptor radionuclide therapy was founded in 2009 by U. Plöckinger and S. Schwartz-Fuchs with great enthusiasm. Data collection and analysis were performed by S. Skrobek-Engel and H. Franz of Lohmann and Birkner in Berlin, Germany. Supported by Covidien Inc., ITG, MDS Nordion, and Eckert and Ziegler Radiopharma GmbH.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hörsch, D. et al. (2013). Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry. In: Baum, R., Rösch, F. (eds) Theranostics, Gallium-68, and Other Radionuclides. Recent Results in Cancer Research, vol 194. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-27994-2_25
Download citation
DOI: https://doi.org/10.1007/978-3-642-27994-2_25
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-27993-5
Online ISBN: 978-3-642-27994-2
eBook Packages: MedicineMedicine (R0)